Study of Atorvastatin Dose Dependent Reduction of Proteinuria
- Registration Number
- NCT00768638
- Lead Sponsor
- Laval University
- Brief Summary
Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Age of 18 and over
- Stage 3 or 4 chronic kidney disease (modified MDRD)
- proteinuria of > 1g/d on ACEi and/or ARB, or proteinuria of > 1g/d with intolerance or contraindication to ACEi and/or ARB
- blood pressure < 130/80 mmHg or < 140/90 mmHg in patients with five or more antihypertensive drugs
- stable renal function
Exclusion Criteria
- rapid progression of renal failure
- immunosuppressive therapy within the past 3 months
- need a renal replacement therapy within 8 months
- definite history of chronic liver disease, or abnormal liver function
- evidence of active inflammatory muscle disease
- definite previous adverse reaction to a statin
- concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin)
- child bearing potential
- known to be poorly compliant with clinic visits or prescribed medication
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atorvastatin 10mg Atorvastatin - Atorvastatin 40mg Atorvastatin -
- Primary Outcome Measures
Name Time Method proteinuria 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôtel-Dieu de Québec Hospital
🇨🇦Quebec, Canada